trandolapril (Mavik)

Subscribe to Selected New Research on trandolapril

251 relevant articles (38 outcomes, 98 trials/studies) found for this Drug

Also Known As:

Mavik; 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid; Abbott brand of trandolapril; Alter brand of trandolapril; Aventis Pharma brand of trandolapril; Aventis brand of trandolapril; Gopten; Hoechst brand of trandolapril; Knoll brand of trandolapril; Odrik; RU 44570; RU-44570; RU44570; Udrik

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Indoles: 69

trandolapril: 251

Experts

1.	Pepine, Carl J: 4 articles (08/2008 - 05/2005)
2.	INVEST Investigators: 2 articles (08/2008 - 10/2006)
3.	Zhou, Qian: 2 articles (08/2008 - 05/2008)
4.	Champion, Annette: 2 articles (08/2008 - 05/2008)
5.	Cohen, Jerome D: 2 articles (08/2008 - 10/2006)
6.	Messerli, Franz H: 2 articles (08/2008 - 10/2006)
7.	Handberg, Eileen: 2 articles (05/2008 - 05/2005)
8.	Takai, Shinji: 2 articles (05/2007 - 07/2002)
9.	Miyazaki, Mizuo: 2 articles (05/2007 - 07/2002)
10.	Kupfer, Stuart: 2 articles (10/2006 - 05/2005)

Related Diseases

1.	Hypertension (High Blood Pressure) 09/01/1993 - "A double-blind, crossover study was carried out to compare the antihypertensive efficacy of the long-acting ACE inhibitor trandolapril 1 mg administered once daily and 0.5 mg twice daily in 31 patients with mild to moderate essential hypertension" 02/01/2007 - "OBJECTIVE: This study evaluated the effectiveness of an escalating-dose regimen of trandolapril in subjects with stage 1 or stage 2 hypertension" 08/01/2006 - "The aim of this study was to assess the influence of trandolapril on blood pressure and ET-1 plasma activity in young patients with essential mild-to-moderate hypertension" 02/01/1996 - "Since some once-daily agents are more effective than others in maintaining antihypertensive effects toward the end of the 24-h dosing interval this study was designed to evaluate the duration of antihypertensive action of trandolapril using 48 h ambulatory blood pressure monitoring (ABPM) in 41 patients with mild-to-moderate essential hypertension" 01/01/1994 - "Long-term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: a multicenter international trial" Get all the results and reference details, order at left...
2.	Heart Failure 07/01/1999 - "In the diabetic group, trandolapril reduced the risk of progression to severe heart failure markedly (RR, 0.38 [0.21 to 0.67]), and no significant reduction of this end point was found in the nondiabetic group" 09/01/1998 - "Thus, whereas the initial systemic vasodilating and inotropic effects did not persist, long-term trandolapril results in sustained neurohormonal modulation, reduced preload, and improved organ perfusion, indicated by a persistent increase in renal blood flow and preservation of renal function in severe heart failure." 01/01/2005 - "Compared with the placebo group, the trandolapril group had a significantly reduced risk of all-cause mortality (relative risk 0.89, 95% CI 0.80-0.99, P=0.03), all-cause hospitalizations (rate ratio 0.92, 95% CI 0.88-0.96, P<0.001), and cardiovascular hospitalizations (rate ratio 0.95, 95% CI 0.91-1.00, P=0.047), including congestive heart failure hospitalizations (rate ratio 0.85, 95% CI 0.77-0.93, P<0.001)" 12/03/2003 - "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment" 04/01/1999 - "Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril." Get all the results and reference details, order at left...
3.	Myocardial Infarction 04/01/2006 - "In the TRACE trial, in patients with reduced left ventricular function after myocardial infarction, trandolapril reduced the frequency of AF" 01/01/2007 - "Long-term treatment of the CAL rats with trandolapril improved the hemodynamic parameters, attenuated the CAL-induced increase in Hsp60 content, the decrease in mitochondrial OCR, and the increase in the mitochondrial TRS content of the viable LV at the 8th week after myocardial infarction" 03/01/2005 - "In this study, the addition of trandolapril did not confer any additional benefit in terms of reducing the incidence of cardiovascular death, myocardial infarction, or coronary revascularization" 01/01/2005 - "METHODS: This study comprises 6676 consecutive patients with acute myocardial infarction screened for entry into the Danish Trandolapril Cardiac Evaluation (TRACE) study" 10/01/2003 - "Recent randomized trials with trandolapril after myocardial infarction and physiologic pacing have given some insight into how this might be accomplished." Get all the results and reference details, order at left...
4.	Hypertrophy 01/01/1994 - "In the mesenteric artery, trandolapril treatment induced a complete regression of the media hypertrophy and a marked decrease in extracellular matrix surface" 01/01/1994 - "Similarly, trandolapril produced a marked decrease in vascular wall hypertrophy in both the mesenteric artery and the aorta" 01/01/1999 - "These results show that together with hypertrophy, the abnormal mechanical properties observed in the coronary arterial wall of SHR were improved by a low dose of trandolapril treatment" 01/01/1994 - "The effects of trandolapril on blood pressure and on cardiac and vascular hypertrophy were analyzed in comparison with the control group" 07/01/1992 - "Trandolapril significantly limited the development of myocardial hypertrophy, decreasing the heart weight and left ventricular hypertrophic area and increasing the left ventricular myocyte nuclear density, but these effects, starting after 3-6 months, were delayed compared to the hemodynamic ones" Get all the results and reference details, order at left...
5.	Left Ventricular Dysfunction 01/01/1998 - "METHODS: Data from the Trandolapril Cardiac Event study, in which 1749 patients with an enzyme verified AMI and echocardiographic evidence of left ventricular dysfunction were randomized in a double-blind manner to treatment with trandolapril or placebo, were retrospectively analysed" 07/01/1998 - "A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction." 01/01/2003 - "In patients with left ventricular dysfunction after myocardial infarction, the large TRACE trial showed that mortality was reduced and life expectancy increased with trandolapril treatment." 01/01/2003 - "Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study." 01/01/2001 - "Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study." Get all the results and reference details, order at left...
92 Diseases and 251 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Verapamil (Calan)
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	Calcium
4.	Insulin (Novolin)
5.	trandolapril (Mavik)
6.	Atenolol (Tenormin)
7.	Calcium Channels (Calcium Channel)
8.	Perindopril
9.	Hydrochlorothiazide (Esidrix)
10.	Ramipril (Altace)
100 Drugs and Important Bio-Agents and 192 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Surgical Instruments (Clip)
3.	Nephrectomy
4.	Ligation
4 Therapies and Procedures and 8 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>